A Case of Surgical Resection in Hepatocellular Carcinoma with Pulmonary Metastasis.
10.17998/jlc.2016.16.2.145
- Author:
Woo Jin JUNG
1
;
Jae Young JANG
;
Jun Seok PARK
;
Hee Jeong LEE
;
Young Kyu CHO
;
Soung Won JEONG
;
Sae Hwan LEE
;
Sang Gyune KIM
;
Sang Woo CHA
;
Young Seok KIM
;
Young Deok CHO
;
Hong Soo KIM
;
Boo Sung KIM
Author Information
1. Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. jyjang@schmc.ac.kr
- Publication Type:Case Report
- Keywords:
Hepatocellular carcinoma;
Metastasis;
Metastasectomy;
Sorafenib
- MeSH:
Carcinoma, Hepatocellular*;
Diagnosis;
Drug Therapy;
Humans;
Lung Diseases;
Metastasectomy;
Neoplasm Metastasis*;
Prognosis;
Recurrence;
Thoracic Surgery, Video-Assisted
- From:Journal of Liver Cancer
2016;16(2):145-150
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hepatocellular carcinoma (HCC) is well known malignancy with poor prognosis, even after resection of the primary tumor. Sorafenib is the first-line treatment in advanced HCC, but the disease control rate of sorafenib is only 43%. Pulmonary metastasectomy in patients with pulmonary metastasis from HCC has been reported to increase long-term survival compared with systemic chemotherapy. Video-assisted thoracic surgery is considered a reliable approach to the diagnosis and treatment of pulmonary diseases with low complication rate. Pulmonary metastasectomy is not universally accepted because of frequent local recurrence, an uncontrollable primary tumor, and frequent multiple pulmonary metastases in HCC, but outcome of pulmonary metastasectomy and adjuvant sorafenib therapy has not been studied. We experienced a patient who had advanced HCC with pulmonary oligometastasis and received surgical resection of the metastatic pulmonary nodule and sorafenib chemotherapy. In advanced HCC with pulmonary oligometastasis, surgical resection of pulmonary metastasis and sorafenib chemotherapy should be considered.
